1. J Med Chem. 2017 Mar 9;60(5):1829-1842. doi: 10.1021/acs.jmedchem.6b01550.
Epub  2017 Feb 22.

Fluorinated Chaperone-β-Cyclodextrin Formulations for β-Glucocerebrosidase 
Activity Enhancement in Neuronopathic Gaucher Disease.

García-Moreno MI(1), de la Mata M(2), Sánchez-Fernández EM(1), Benito JM(3), 
Díaz-Quintana A(3), Fustero S(4)(5), Nanba E(6), Higaki K(6), Sánchez-Alcázar 
JA(2), García Fernández JM(3), Ortiz Mellet C(1).

Author information:
(1)Department of Organic Chemistry, Faculty of Chemistry, University of Sevilla 
, c/Profesor García González 1, 41011 Sevilla, Spain.
(2)Centro Andaluz de Biología del Desarrollo (CABD), CSIC, Universidad Pablo de 
Olavide, and Centro de Investigación Biomédica en Red, Enfermedades Raras 
(CIBERER), Instituto de Salud Carlos III, Carretera de Utrera Km 1, 41013 
Sevilla, Spain.
(3)Instituto de Investigaciones Químicas (IIQ), CSIC, and Universidad de 
Sevilla, Avda. Américo Vespucio 49, E-41092 Sevilla, Spain.
(4)Departamento de Química Orgánica, Universidad de Valencia , 46100 Burjassot, 
Spain.
(5)Laboratorio de Moléculas Orgánicas, Centro de Investigación Príncipe Felipe , 
46012 Valencia, Spain.
(6)Division of Functional Genomics, Research Center for Bioscience and 
Technology, Tottori University , 86 Nishi-cho, Yonago 683-8503, Japan.

Amphiphilic glycomimetics encompassing a rigid, undistortable nortropane 
skeleton based on 1,6-anhydro-l-idonojirimycin and a polyfluorinated antenna, 
when formulated as the corresponding inclusion complexes with β-cyclodextrin 
(βCD), have been shown to behave as pharmacological chaperones (PCs) that 
efficiently rescue lysosomal β-glucocerebrosidase mutants associated with the 
neuronopathic variants of Gaucher disease (GD), including the highly refractory 
L444P/L444P and L444P/P415R single nucleotide polymorphs, in patient 
fibroblasts. The body of work here presented includes the design criteria for 
the PC prototype, the synthesis of a series of candidates, the characterization 
of the PC:βCD complexes, the determination of the selectivity profiles toward a 
panel of commercial and human lysosomal glycosidases, the evaluation of the 
chaperoning activity in type 1 (non-neuronopathic), type 2 (acute 
neuronopathic), and type 3 (adult neuronopathic) GD fibroblasts, the 
confirmation of the rescuing mechanism by immunolabeling, and the analysis of 
the PC:GCase binding mode by docking experiments.

DOI: 10.1021/acs.jmedchem.6b01550
PMID: 28171725 [Indexed for MEDLINE]